Streetbeat News

RETA

Reata Pharmaceuticals Inc

https://reatapharma.com/

CEO

J. Warren Huff

Employees

372

Industry

Pharmaceutical Preparation Manufacturing

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Open

172.34

Mkt cap

6.6B

Volume

1.9M

High

172.46

P/E Ratio

-66.29

52-wk high

172.46

Low

172.32

Div yield

N/A

52-wk low

21.83

The Global Data report indicates a decrease in pharma sector M&A deals in Q3 2023 compared to Q2 2023, with a 28% drop in deal value and a 9% drop in deal volume. However, PricewaterhouseCoopers forecasts a positive outlook for 2024, expecting a return to pre-pandemic levels of M&A activity. Notable deals in 2023 include acquisitions by Pfizer, Bristol Myers Squibb, Merck, AbbVie, Biogen, and Astellas Pharma.

Portfolio Pulse from Vandana Singh

December 29, 2023 | 12:04 pm

A gold miner with strong fundamentals, including a Piotroski F-Score of 8 and a Relative Strength Index (RSI) below 20, is considered undervalued and a good buying opportunity. The miner has high margins, with all-in sustaining costs of about $700 per ounce, compared to an industry average of $1,360 per ounce. However, there is some political risk due to one of the company's properties being in a state in Mexico with a history of strikes. The SPDR Gold Shares ETF (GLD) and the VanEck Gold Miners ETF (GDX) are also mentioned in the context of gold and gold miners' performance.

Portfolio Pulse from David Pinsen

October 05, 2023 | 1:58 pm

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced that its stockholders have approved the company's acquisition by Biogen Inc. Approximately 99.65% of the votes cast by the company's Class A and Class B common stockholders approved the merger. The expected closing date of the merger is September 26, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 2:14 pm

Sanofi is reported to have been the mystery buyer in a bidding war for Reata Pharmaceuticals, according to Bloomberg.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 7:36 pm

Reata Pharmaceuticals (NASDAQ:RETA) has received a mix of bullish and indifferent analyst ratings in the last quarter. In the last 3 months, 13 analysts have offered 12-month price targets for the company, with an average price target of $149.92, a 42.78% increase from the previous average price target of $105.00.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 7:00 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated a Neutral rating on Reata Pharmaceuticals (NASDAQ:RETA) and maintained a price target of $172.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 2:26 pm

Benzinga's options activity scanner has identified unusual trading activity in 10 health care stocks. The stocks include Johnson & Johnson (JNJ), Moderna (MRNA), Apellis Pharmaceuticals (APLS), Pfizer (PFE), Boston Scientific (BSX), CVS Health (CVS), Zimmer Biomet Holdings (ZBH), Cassava Sciences (SAVA), Reata Pharmaceuticals (RETA), and Doximity (DOCS). The scanner tracks large transactions, known as 'whale alerts', which can indicate the sentiment of large investors and potentially predict market movements.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 5:35 pm

Benzinga's options activity scanner has identified significant trading activity in the options of 10 healthcare stocks. The stocks include Johnson & Johnson (JNJ), DexCom (DXCM), Moderna (MRNA), Eli Lilly and Company (LLY), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Novo Nordisk (NVO), Pfizer (PFE), Veeva Systems (VEEV), and Reata Pharmaceuticals (RETA). The options activity ranges from bullish to bearish sentiment, with varying expiration dates and strike prices.

Portfolio Pulse from Benzinga Insights

August 08, 2023 | 5:35 pm

Citigroup analyst Yigal Nochomovitz has downgraded Reata Pharmaceuticals from Buy to Neutral, while raising the price target from $127 to $172.5.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 12:01 pm

Barclays analyst Carter Gould has downgraded Reata Pharmaceuticals from Overweight to Equal-Weight, while raising the price target from $110 to $172.

Portfolio Pulse from richadhand@benzinga.com

August 01, 2023 | 9:29 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.